Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Clinical pathological characteristics associated with NSLNs

From: Spatial organization of dendritic cells within tumor draining lymph nodes impacts clinical outcome in breast cancer patients

  Tumor free NSLNs (NSLN-) Tumor invaded NSLNs (NSLN+)
Number of patients n=50 n=22
Median age of patients (years) median : 47 range: 32-80 median: 54 range: 32-76
Primary tumor size (cm) median: 2.05 range: 0.30-7.00 median: 2.15 range: 0.80-7.00
Stage   
I 5/50 (10%)
IIA 20/50 (40%) 4/22 (18.2%)
IIB 13/50 (26%) 4/22 (18.2%)
III 7/50 (14%) 9/22 (41%)
Unknown 5/50 (10%) 5/22 (22.7%)
Grade   
I 8/50 (16%)
II 30/50 (60%) 8/22 (36.3%)
III 9/50 (18%) 9/22 (41%)
Unknown 3/50 (6%) 5/22 (22.7%)
Molecular subtype   
Luminal A 23/50 (46%) 8/22 (36.3%)
Luminal B 10/50 (20%) 3/22 (13.6%)
HER2 2/50 (4%) 4/22 (18.2%)
Basal 3/50 (6%) 2/22 (9%)
Unknown 12/50 (24%) 5/22 (22.7%)
ER status   
Positive 41/50 (82%) 15/22 (68.1%)
Negative 6/50 (12%) 7/22 (31.9%)
Unknown 3/50 (6%)
PR status   
Positive 38/50 (76%) 13/22 (59%)
Negative 9/50 (18%) 9/22 (41%)
Unknown 3/50 (6%)
HER2/neu expression   
Positive 12/50 (24%) 7/22 (31.8%)
Negative 26/50 (52%) 10/22 (45.5%)
Unknown 12/50 (24%) 5/22 (22.7%)